Australia agreement for Lisburn biotech firm Cirdan
Lisburn biotech firm Cirdan has exported its blood-testing technology to Australia.
Cirdan ULTRA won a contract worth an undisclosed sum with Australia's National Blood Authority.
Cirdan founder Hugh Cormican said the deal would open doors for the company in the future.
The company is developing an internet interface with NBA's existing BloodNet portal allowing laboratories to use Cirdan's system for blood testing operations.
The NBA uses Bloodnet to monitor the stock of blood and automates the requests for new blood as well as what is happening to the stock of blood.
Cirdan's ULTRA LIS system is already being used in hospital and clinical laboratories which process almost a quarter of Australia's total blood supplies.
Mr Cormican said: "The NBA contract for BloodNet will help reinforce our position as the market leader in Australia and lead to further business in this and other global markets.
"The NBA is a very impressive organisation and we are delighted to work with them to develop an interface to BloodNet. We plan to have the interface available in June to roll out to our customers."
He said Cirdan technology allowed for faster and more accurate data for use in treating patients, leading to reduced waiting lists and improved outcomes.
Nathan Kruger, NBA deputy chief information officer, said: "Laboratories that use ULTRA LIS currently process 24% of total blood supplies nationally and these laboratories have been clamouring for such an interface. With the ink on the contract barely dry, Cirdan has already commenced development."
Cirdan was established by Mr Cormican in 2010. It employs 20 people in design and development of medical diagnostic equipment..